References

218

8. REFERENCES

1. Ojewole AO, John. Analgesic, anti-inflammatory and hypoglycaemic effects of Rhus

chirinensis (Baker F.) [Anacardiaceae] stem-bark aqueous extract in mice and rat. J

Ethnopharmacol 2007;113:338-45.

2. Fowler. LM, ME Williams. Use of unproven therapies by people with alzheimers disease.

Journal of the American Geriatrics Society 1995; 43:747-750.

3. MacKay J, Mensah G. The atlas of heart disease and stroke. World Health Organization,

Geneva. 2004.

4. . Reddy KS. Cardiovascular diseases in India. World Health Stat. Q. 1993; 46: 101–107.

5. Aronow, W.S., 2006. Epidemiology, pathophysiology, prognosis, and treatment of

systolic and diastolic heart failure. Cardiol. Rev. 14, 108–124.

6. Stocker, R.: The ambivalence of vitamin E in atherogenesis. Trends Biochem. Sci., 24,

219–223, 1999.

7. Bela Shah & Prashant Mathur. Surveillance of cardiovascular disease risk factors in

India: The need & scope. Indian J Med Res 132, November 2010, pp 634-642

8. Ru Zhou a, Qingbin Xu b, Ping Zheng a, Lin Yan a, Jie Zheng a, Guidong Dai.

Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in

rat. European Journal of Pharmacology 586 (2008) 244–250.

9. Jai Ashish Tilak-Jain and Thomas Paul Asir Devasagayam. Cardioprotective and Other

Beneficial Effects of Some Indian Medicinal Plants. J. Clin. Biochem. Nutr., 38, 9–18,

January 2009.

References

219

10. Havsteen, BH. The biochemistry and medical significance of the flavonoids.

Pharmacology and Therapeutics 2002; 96: 67-202.

11. Mladenka, P, Zatloukalova, L, Filipsky, T, Hrdina, R. Cardiovascular effects of

flavonoids are not caused only by antioxidant activity. Free radical Biology and Medicine

2010; 49: 963-975.

12. Roden DM, Antiarrhythmic drugs. In: Laurance LB, Lazo JS, Parkar KL, Editor.

Goodman & Gillman. The pharmacological Basics of Therapeutics. 11 edition.

Newyork:Mcgraw Hill, 2006:899-932.

13. Paul Khairy and Seshadri Balaji. Cardiac Arrhythmias In Congenital Heart Diseases.

Indian Pacing and Electrophysiology Journal 9 (6): 299-317 (2009).

14. Thireau J, Pasquié JL, Martel E, Le Guennec JY, Richard S. New drugs vs. old concepts:

a fresh look at antiarrhythmics. Pharmacol Ther. 2011 Nov;132(2):125-45.

15. B. Shah, C. Varghese, Sandeep et al. Epidemiology of type 2 diabetes: Indian scenario.

Indian J Med Res 2007; 125(3):217-30.

16. Jared Diamond. Diabetes in India research: news and views 2011;469:479

17. Tripathi KD. Essentials of medical pharmacology.6th ed, Jaypee publishers 2007.235-236

18. Rang. H.P, Dale. M.M. Pharmacology 6th ed. Churchill livingstone, elsivier publications

2009.p-397.

19. Natarajan R, Louisa M. The role of epigenetic in the pathology of diabetic complications

2010;1:1

20. Diabetic neuropathies: The nerve damage of diabetes, U.S. Department of health and

human services, national institutes of health NIH publication no. 09–3185,2009.

References

220

21. Muller.K.Characterization & treatment of large sensory fiber Peripheral neuropathy in

mice 2003 B.S., Emory University 2003.

22. Balasubramanyan .S, Sharma .S. Protective Effect Of Adenosine In Diabetic Neuropathic

Pain Is Mediated Through Adenosine A1-Receptors.Indian J Physiol

Pharmacol.2008;52(3):233–242.

23. Negi.G, Kumar.A, Ravinder.K,et al. Neuropharmacology Functional And Biochemical

EvidenceIndicating Beneficial Effect Of Melatonin And Nicotinamide Alone And In

Combination In Experimental Diabetic Neuropathy.Neuropharmacology.2010;58(1):585-

592.

24. Ahamed.M, et al. A Review On Diabetic Neuropathy And

Nephropathy.Ijpsr.2012;3(2):300-304.

25. Yamamoto.H,Shimoshige.Y,Yamaji.T,etalPharmacological Charact -erization Of

Standard Analgesics On Mechanical Allodynia In Streptozotocin-Induced Diabetic

Rats.Neuropharmacology 2009;57(1):403–08.

26. Harleen Kaur Sandhar, Bimlesh Kumar, Sunil Prasher et al. A Review of Phytochemistry

and Pharmacology of Flavonoids. Internationale Pharmaceutica Sciencia. 2012;1(1):25-

41.

27. The Wealth of India, Raw material, Ambasta SP, editor-in-chief, Vol. ;Ca ci

publication& information directorate, CSIR: New Delhi;1998:13-14.

28. Chakraborthy GS, Badujar RS, Purdeshi CR. Analgesic activity of choloroform extract of

Caesalpinia pulcherrima. Journal of Pharmacy Research 2009;2(77): 1199-1200.

29. Gautham R, Saklani A, Jachak SM. Indian medicinal: Plant as a source of

antimyobacterial agents. J Ethanopharmacol 2007;110: 200-34.

References

221

30. Sharma R K; Rajani G. P. Sharma V et al. Effect of Ethanolic and Aqueous Extracts of

Bauhinia Variegata Linn. on Gentamicin-Induced Nephrotoxicity in Rats Ind J Pharma

Edu Res 2011;45 (2):192-198.

31. Naresh Singh Gill, Ramandeep Kaur, Rashmi Arora and Manoj Bali. Phytochemical

Investigation of Caesalpinia crista Seed Extract for their Therapeutic Potential. Research

Journal of Medicinal Plant,2012; 6: 100-107.

32. Gill, N.S., P. Sharma, J. Bajwa, K. Dhiman, S. Sood, P.D. Sharma and M. Bali,

2010. Study on Cucumis melo var. utilissimus seeds for the therapeutic potential. J. Plant

Sci., 5: 248-255

33. www.healthinitiative.org

34. Hughes, K. and Ong, C.N.: Vitamins, selenium, iron and coronary heart disease risk in

Indians, Malays and Chinese in Singapore. J. Epidemiol. Comm. Health 1998:52:181–

185.

35. Packer, L. and Ong, A.S.H.: Biological Oxidants and Antioxidants: Molecular

Mechanisms and Health Effects. Cham paign: AOCS Press, 1998.

36. Harrison, D., Griendling, K.K., Landmesser, U., Hornig, B. and Drexler, H.: Role of

oxidative stress in atherosclerosis. Am. J. Cardiol 2003; 91:7A–11A.

37. Noguchi, N. and Niki, E.: Phenolic antioxidants: a rationale for design and evaluation of

novel antioxidant drug for atherosclerosis. Free Rad. Biol. Med 2000;28:1538–1546.

38. Scartezzini, P. and Speroni, E.: Review on some plants of Indian traditional medicine

with antioxidant activity. J Ethnopharmacol 2000;71: 23–43.

References

222

39. Jai Ashish Tilak-Jain and Thomas Paul Asir Devasagayam. Cardioprotective and Other

Beneficial Effects of Some Indian Medicinal Plants. J. Clin. Biochem. Nutr 2006

Jan;38:9–18.

40. Reeve, J.L.V., A.M. Duffy and T. O`Brien. Don't loss heart therapeutic value of apoposis

prevention in the treatment of cardiovascular disease. J. Cell. Mol. Med 2005;9: 609-622.

41. Robbins and Cotran PATHOLOGIC BASIS OF DISEASE . Seventh Edition. 2004: 633-

638.

42. Tripathi KD. Essential of medical Pharmacology. Sixth edition. Jaypee Brothers Medical

Publishers (P) Ltd. 2009,: 501-502. .

43. Sushma, K.S., A. Jaydeep and J.S.S. Kumar. Effect of carnitine on malondialdehyde,

taurine and glutathione levels in heart of rats subjected to myocardial stress by

isoproteranol. Ind. J. Exp. Biol 1989;27: 134-137.

44. Grimm, D., D. Elsner and H. Schunkert. Development of heart failure following

isoproterenol administration in the rat: Role of rennin angiotensin system. Cardiovas

Res1998;37: 91-100.

45. Rupp, H., K.S. Dhalla and N.S.J. Dhalla. Cardiovasc. Pharmacol 1994;24: 16-16.

46. Dhalla, N.S., R.M. Temsah and T. Netticadan. Role of oxidative stress in cardiovascular

diseases. J. Hypertens 2010;18: 655-673.

47. Hu, A., X. Jiao, E. Gao, J.K. Walter and S. Sharif-Azad et al. Chronic beta-adrenergic

receptor stimulation induces cardiac apoptosis and aggravates myocardial

ischemia/reperfusion injury by provoking inducible nitric-oxide synthase-mediated

nitrative stress. J. Pharmacol. Exp. Ther. 2006;318: 469-475.

References

223

48. Pinn, G.,. Herbs and cardiovascular disease. From past to present. Aust. Fam. Physician

2000; 29: 1149-1153.

49. Weisburger, J.H.. Lifestyle, health and disease prevention: The underlying mechanisms.

Eur. J. Cancer Prev 2002;11: 1-7.

50. Suchalatha, S. and C.S.S. Devi. Protective effect of Terminalia chebula against lysosomal

enzyme alterations in isoproterenol induced cardiac damage in rats. Exp. Clin. Cardiol.

2005;10: 91-95.

51. Bafna, P.A and R. Balaraman. Antioxidant activity of DHC-1, an herbal formulation, in

experimentally induced cardiac and renal damage. Phytother. Res 2005;19: 216-222.

52. Shashikumar, C.S. and C.S. Shyamaladevi. Protective effect of Abana?, a poly-herbal

formulation, on isoproterenol-induced myocardial infarction in rats. Ind. J. Pharmacol

2000;32: 198-201

53. Roach: Introductory Clinical Pharmacology, 8 Edition Roach:e: Introductory Clinical

Pharmacology (7th Ed) and Lww 2007 Drug Guide.

54. Keating MT, Sanginethi MC, Molecular and celuular machanism of cardiac arrythmia.

Cell 2001;104:569-80

55. Tripathi KD. Essential of medical Pharmacology. Sixth edition. Jaypee Brothers Medical

Publishers (P) Ltd. 2009,: 508-512 .

56. Vaughea- Willams EM. Classification of antiarrythmics. In: Sandoe E, Flevstd-Jensen E,

Olsen KH, editor. Symposium on cardiac arrythmia, Elsinor, Denmark: Ad astra,

Sodertalj, Swden 1970.

57. L.K. Bhatt, K. Nandakumar, S.L. Bodhankar. Experimental animal models to induce

cardiac arrhythmias. Indian J Pharmacol December 2005.;37 (6): 348-357.

References

224

58. European Heart Rhythm Association, European Association for Cardio- Thoracic

Surgery; Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task

Force for the Management of Atrial Fibrillation of the European Society of Cardiology

(ESC). Eur Heart J. 2010;31(19):2369–2429.

59. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the

Management of Patients with Atrial Fibrillation:. Circulation. 2006;114(7):e257–e354.

60. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the

management of patients with atrial fibrillation (updating the 2006 guideline): a report of

the American College of Cardiology Foundation/American Heart Association Task Force

on Practice Guidelines. Circulation. 2011;123(1):104–123.

61. Komatsu T, Tachibana H, Sato Y, Ozawa M, Kunugida F, Nakamura M. Efficacy of

antiarrhythmic drug therapy in preventing recurrence of atrial fibrillation and long-term

cardiovascular prognosis in patients with asymptomatic paroxysmal atrial f ibrillation. Int

Heart J. 2010;51(2):98–104.

62. Ravens U. Novel pharmacological approaches for antiarrhythmic therapy. Naunyn

Schmiedebergs Arch Pharmacol. 2010;381(3): 187–193.

63. Cho HC, Marbán E. Biological therapies for cardiac arrhythmias: can genes and cells

replace drugs and devices? Circ Res. 2010;106(4):674–685.

64. Hodgson-Zingman DM, Karst ML, Zingman LV, et al. Atrial natriuretic peptide

frameshift mutation in familial atrial fibrillation. N Engl J Med. 2008;359(2):158–165.

65. Olson TM, Michels VV, Ballew JD, et al. Sodium channel mutations and susceptibility to

heart failure and atrial fibrillation. JAMA. 2005;293(4):447–454.

References

225

66. Chen YH, Xu SJ, Bendahhou S, et al. KCNQ1 gain-of-function mutation in familial atrial

fibrillation. Science. 2003;299(5604):251–254.

67. Yang Y, Xia M, Jin Q, et al. Identification of a KCNE2 gain-of-function mutation in

patients with familial atrial fibrillation. Am J Hum Genet. 2004;75(5):899–905.

68. Gudbjartsson DF, Holm H, Gretarsdottir S, et al. A sequence variant in ZFHX3 on 16q22

associates with atrial fibrillation and ischemic stroke. Nat Genet. 2009;41(8):876–878.

69. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by

ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659–666.

70. Allessie MA, Bonke FI, Schopman FJ. Circus movement in rabbit atrial muscle as a

mechanism of tachycardia III. The “leading circle” concept: a new model of circus

movement in cardiac tissue without the involvement of an anatomical obstacle. Circ Res.

1977;41(1):9–18.

71. Davidenko JM, Pertsov AV, Salomonsz R, Baxter W, Jalife J. Stationary and drifting

spiral waves of excitation in isolated cardiac muscle. Nature. 1992;355(6358):349–351.

72. Pertsov AM, Davidenko JM, Salomonsz R, Baxter WT, Jalife J. Spiral waves of

excitation underlie reentrant activity in isolated cardiac muscle. Circ Res.

1993;72(3):631–650.

73. Ravens U, Cerbai E. Role of potassium currents in cardiac arrhythmias. Europace.

2008;10(10):1133–1137.

74. Thomas D, Karle CA, Kiehn J. The cardiac hERG/IKr potassium channel as

pharmacological target: structure, function, regulation, and clinical applications. Curr

Pharm Des. 2006;12(18):2271–2283.

References

226

75. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during

atrial fibrillation. Cardiovasc Res. 2002;54(2):230–246.

76. Workman AJ. Cardiac adrenergic control and atrial fibrillation. NaunynSchmiedebergs

Arch Pharmacol. 2010;381(3):235–249.

77. Jons C, Raatikainen P, Gang UJ, et al. Autonomic dysfunction and new-onset atrial

fibrillation in patients with left ventricular systolic dysfunction after acute myocardial

infarction: a CARISMA substudy. J Cardiovasc Electrophysiol. 2010;21(9):983–990.

78. Sheng X, Scherlag BJ, Yu L, et al. Prevention and reversal of atrial fibrillation

inducibility and autonomic remodeling by low-level vagosympathetic nerve stimulation.

J Am Coll Cardiol. 2011;57(5): 563–571.

79. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-

control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation

(STAF) study. J Am Coll Cardiol. 2003;41(5):1690–1696.

80. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation –

Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomized trial. Lancet.

2000;356(9244):1789–1794.

81. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm

control in patients with recurrent persistent atrial fibrillation. N Engl J Med.

2002;347(23):1834–1840.

82. Wyse DG, Waldo AL, DiMarco JP, et al. Atrial Fibrillation Follow-up Investigation of

Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm

control in patients with atrial fibrillation. N Engl J Med. 2002;347(12):1825–1833.

References

227

83. Opolski G, et al. Rate control vs rhythm control in patients with nonvalvular persistent

atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT

CAFE) Study. Chest. 2004;126(2):476–486.

84. Thomas D, Kathofer S, Zhang W, et al. Acute effects of dronedarone on both components

of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium

channels. Br J Pharmacol. 2003;140(5):996–1002.

85. Kathofer S, Thomas D, Karle CA. The novel antiarrhythmic drug dronedarone:

comparison with amiodarone. Cardiovasc Drug Rev. 2005;23(3):217–230.

86. Schweizer PA, Becker R, Katus HA, Thomas D. Dronedarone: current evidence for its

safety and efficacy in the management of atrial fibrillation. Drug Des Devel Ther.

2011;5:27–39.

87. Jaïs P, Shah DC, Haïssaguerre M, et al. Efficacy and safety of septal and left-atrial linear

ablation for atrial fibrillation. Am J Cardiol. 1999;84(9A):139R–146R.

88. Pappone C, Rosanio S, Oreto G, et al. Circumferential radiofrequency ablation of

pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. Circulation.

2000;102(21): 2619–2628.

89. Nademanee K, McKenzie J, Kosar E, et al. A new approach for catheter ablation of atrial

fibrillation: mapping of the electrophysiologic substrate. J Am Coll Cardiol.

2004;43(11):2044–2053.

90. Pokushalov E, Romanov A, Artyomenko S, et al. Ganglionated plexi ablation for

longstanding persistent atrial fibrillation. Europace. 2010;12(3):342–346.

References

228

91. Gaita F, Caponi D, Scaglione M, et al. Long-term clinical results of 2 different ablation

strategies in patients with paroxysmal and persistent atrial fibrillation. Circ Arrhythm

Electrophysiol. 2008;1(4):269–275.

92. Takahashi A. Catheter ablation is established as a treatment option for atrial fibrillation –

is catheter ablation established as a treatment option of atrial fibrillation? (Pro). Circ J.

2010;74(9):1972–1977.

93. Jaïs P, Packer DL. Ablation vs drug use for atrial fibrillation. Eur Heart J Suppl.

2007;9(Suppl G):G26–G34.

94. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of

clinical classification schemes for predicting stroke: results from the National Registry of

Atrial Fibrillation. JAMA.2001;285(22):2864–2870.

95. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for

anticoagulation: stroke risk stratification in patients taking aspirin. Circulation.

2004;110(16):2287–2292.

96. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with

atrial fibrillation. N Engl J Med. 2009;361(12): 1139–1151.

97. Eikelboom JW, O’Donnell M, Yusuf S, et al. Rationale and design of AVERROES:

apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who

have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J.

2010;159(3): 348–353.e1.

98. Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and

other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and

rationale. Am Heart J. 2010;159(3): 331–339.

References

229

99. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa

inhibition compared with vitamin K antagonism for prevention of stroke and Embolism

Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J.

2010;159(3):340–347.

100. Dawson AG, Asopa S, Dunning J. Should patients undergoing cardiac surgery

with AF have left atrial appendage exclusion? Interact Cardiovasc Thorac Surg.

2010;10(2):306–311.

101. Kanderian AS, Gillinov AM, Pettersson GB, Blackstone E, Klein AL. Success of

surgical left atrial appendage closure: assessment by transesophageal

echocardiography. J Am Coll Cardiol. 2008;52(11):924–929.

102. Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage

transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with

non-rheumatic atrial fibrillation: results from the international multi-center feasibility

trials. J Am Coll Cardiol. 2005;46(1):9–14.

103. Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the

WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation.

J Am Coll Cardiol. 2007;49(13):1490–1495.

104. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial

appendage versus warfarin therapy for prevention of stroke in patients with atrial

fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534–542.

105. Amit G, Kikuchi K, Greener ID, Yang L, Novack V, Donahue JK. Selective

molecular potassium channel blockade prevents atrial fibrillation. Circulation.

2010;121(21):2263–2270.

References

230

106. Goldman P: Herbal medicines today and the roots of modern pharmacology. Ann

Intern Med 135:594, 2001

107. Sinatra ST, Frishman WH, Peterson SJ, et al: Use of alternative/complementary

medicine in treating cardiovascu-lar disease, in Frishman WH, Sonnenblick EH, Sica

DA (eds): Cardiovascular Pharmacotherapeutics (ed 2). New York, NY, McGraw

Hill, 2003, p 857

108. Slifman NR, Obermeyer WR, Aloi BK, et al: Contamina- tion of botanical dietary

supplements by Digitalis lanata. N Engl J Med 339:806, 1998

109. Radford DJ, Gillies AD, Hinds JA, et al: Naturally occur-ring cardiac glycosides.

Med J Aust 144:540, 1986 .

110. Zeng X-H, Zeng X-J, Li Y-Y: Efficacy and safety of ber-berine for congestive

heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J

Cardiol 92:173, 2003.

111. Rauwolfia alkaloids, in USP DI, Vol I: Drug Information for the Health Care

Professional (ed 16). Rockville, MD, United States Pharmacopeial Convention, 1996

112. Sutter MC, Wang YX: Recent cardiovascular drugs from Chinese medicinal

plants. Cardiovasc Res 27:1891, 1993

113. Ody P: The Complete Medicinal Herbal. New York, NY, Dorling Kindersley,

1993

114. Kuramochi T, Chu J, Suga T: Gou-teng (from Uncaria rhynchophylla Miquel)

induced endothelium-dependent and independent relaxations in the isolated rat aorta.

Life Sci 54:2061, 1994

115. Chang Q, Zuo Z, Harrison F, et al: Hawthorn. J Clin Pharmacol 42:605, 2002

References

231

116. Vibes J, Lasserre B, Gleye J, et al: Inhibition of throm-boxane A2 biosynthesis in

vitro by the main components of Crataegus oxyacantha (hawthorn) flower heads.

Prostaglan-dins Leukotrienes Essent Fatty Acids 50:173, 1994

117. Shanthi S, Parasakthy K, Deepalakshmi PD, et al: Hypolipidemic activity of

tincture of Crataegus in rats. Indian J Biochem Biophys 31:143, 1994

118. Nasa Y, Hashizume H, Hoque AN, et al: Protective effect of Crataegus extract on

the cardiac mechanical dysfunction in isolated perfused working rat heart. Arzneim-

Forsch 43:945, 1993

119. Blesken R: Crataegus in cardiology (German). Fortschr Med 110:290, 1992

120. Baughman KL, Bradley DJ: Hawthorn extract: Is it time to turn over a new leaf?

Am J Med 114:700, 2003

121. Pittler MH, Schmidt K, Ernst E: Hawthorn extract for treating chronic heart

failure: Meta-analysis of randomized trials. Am J Med 114:665, 2003

122. Lin SG, Zheng XL, Chen QY, et al: Effect of Panax notoginseng saponins on

increased proliferation of cultured aortic smooth muscle cells stimulated by

hypercholester-olemic serum. Zhongguo Yao Li Xue Bao 14:314, 1993

123. Ackermann RT, Mulrow CD, Ramirez G, et al: Garlic shows promise for

improving some cardiovascular risk factors. Arch Intern Med 161:813, 2001

124. Silagy CA, Neil HA: A meta-analysis of the effect of garlic on blood pressure. J

Hypertens 12:463, 1994

125. Silagy C, Neil A: Garlic as a lipid lowering agent. A meta-analysis. J R Coll

Physicians Lond 28:39, 1994

126. Ernst E: The risk– benefit profile of commonly used herbal therapies: Ginkgo, St.

References

232

John’s wort, ginseng, echinacea, saw palmetto, and kava. Ann Intern Med 136:42,

2002

127. Tyler VE: Herbs of choice, in The Therapeutic Use of Phytomedicinals. New

York, NY, Pharmaceutical Product Press, 1994

128. Offord EA, Mace K, Ruffieux C, et al: Rosemary compo-nents inhibit

benzo(a)pyrene-induced genotoxicity in human bronchial cells. Carcinogenesis

16:2057, 1995

129. Haraguchi H, Saito T, Okamura N, et al: Inhibition of lipid peroxidation and

superoxide generation by diterpenoids from Rosmarinus officinalis. Planta Med

61:333, 1995

130. Larrondo JV, Agut M, Calvo-Torras MA: Antimicrobial activity of essences from

labiates. Microbios 82:171, 1995

131. al-Hader AA, Hasan ZA, Aqel MB: Hyperglycemic and insulin release inhibiting

effects of Rosmarinus officinalis. J Ethnopharmacol 43:217, 1994

132. Tyler VE: The Honest Herbal: A Sensible Guide to the Use of Herbs and Related

Remedies (ed 3). New York, NY, Pharmaceutical Product Press, 1993

133. Bouskela E, Cyrino FZ, Marcelon G: Possible mecha-nisms for the inhibitory

effect of Ruscus extract on increased microvascular permeability induced by

histamine in hamster cheek pouch. J Cardiovasc Pharmacol 24:281, 1994

134. Berg D: Venous tonicity in pregnancy varicose veins (German). Fortschr Med

110:67, 1992

135. Tyler VE: The Honest Herbal: A Sensible Guide to the Use of Herbs and Related

Remedies (ed 3). New York, NY, Pharmaceutical Product Press, 1993

References

233

136. Shekelle PG, Hardy ML, Morton SC, et al: Efficacy and safety of ephedra and

ephedrine for weight loss and athletic performance: A meta-analysis. JAMA

289:1537, 2003

137. Chan TYK, Chan JCN, Tomlinson B, et al: Chinese herbal medicines

revisited: The Hong Kong perspective. Lancet 342:1532, 1993

138. Horowitz RS, Feldhaus K, Dart RC, et al: The clinical spectrum of Jin Bu Huan

toxicity. Arch Intern Med 156:899, 1996

139. Anders A. F. Structure and function interaction in therapeutic response. J Diab

Comp 1992; 63.

140. Types of Neuropathy/ accesson25.5.12/ availablefromURL/http://

diabeetes.emedtv.com /diabetic-neuropathy/ types-of-diabetic-neuropathy.html.

141. Painful Diabetic Neuropathy in clinical practice/access on 12.5.12/available from

the URL 10.1007/978-0-85729-488-3_2.

142. Harrisons. Principles of Internal medicine, 17th ed. fauci braun wald kasper

publishers New York.2006;2: 2651-2654.

143. Cesen. R.M, Calcutt N. Gabapentin prevents hyperalgesia during the formalin test

in diabetic rats. Neuroscience Letters. 1999; 262:101–104.

144. Experimental models of painful diabetic neuropathy Nigel A. Calcutt. Department

of Pathology, University of California San Diego, La Jolla, CA92093, USA

145. Vincent .M, Sinlin. H T, Feldman. E et al. Diabetic neuropathy mechanism to

management. Pharmacology and therapeutics 2008;120:1–34

References

234

146. Nakamura.J, Koh.N, Sakakibara.N-polyol pathway 2,3 diphosphoglycerates in

erythrocytes and diabetic neuropathy in rats. European journal of pharmacology 1995;

294:207-214.

147. Taliyan R, Sharma P.L. Update and novel pharmacological strategy for relief of

pain. Journal of medical sciences.10:93-109.

148. Mizisin. A. Schwann cell in diabetic neuropathy. Advances in molecular and cell

biology 2004;31:1105-1116.

149. Doupis. J, and Veves. A. Antioxidants, Diabetes, and Endothelial dysfunction.

Diabetes and cardiovascular risk.2007

150. Brownlee. M. The pathobiology of diabetic complications.Diabetes, 2005;54.

151. Said. G. Diabetic Neuropathy- A review. Nature clinical practice neurology

2007;3(6):331-340.

152. Charles E. Argoff, B. Eliot Cole, David A. Consensous guidelines: Assessment,

diagnosis, and the treatment of diabetic peripheral neuropathic pain 2006; 81(4)

153. Rana A.C, Gangwani.S, Sharma R et al. Potential Interventions in the

management of neuropathic pain 2011; 1(3):328-334.

154. Bril.V. Filling the gap emerging treatments for diabetic neuropathy 2004;8(a).

155. Carolina M. Casellini and Aaron I. Vinik Recent advances in the treatment of

diabetic neuropathy. Endocrinal diabetes 2006; 13:1-153.

156. Lenzen. S. The mechanism of alloxan and streptozotocin induced diabetes.

Diabetolgia. 2008; 51:216-226.

References

235

157. Robert J. Konard .E, Mikoloenko.I et al. The potential mechanism of the

diabetogenic action of streptozotocin : inhibition of pancreatic b-cell O-GlcNAc-

selectiveN-acetyl-b-D-glucosaminidase. Biochem. J 2001; 356:31

158. Weerateerangkull P1, Praputpittaya C1, Banjerdpongchai R Effects of Ascorbic

Acid on Streptozotocin-induced Oxidative Stress and memory Impairment in rats the

journal of physiological sciences 2008;20(2).

159. Sharma.V. Streptozotocin: An Experimental tool in diabetes and

alziemers’disease. Ijprd 2010;2(1)

160. Valenca. M, Nessler.V, Moore. K. Diabetic Peripheral Neuropathies: A

Morphometric overview International Journal of Morphology 2010; 28(1):51-64.

161. Dominique Sigaudo-Rousse. Et al. Diabetic Neuropathy in Animal Models. Drug

Discovery Today: Disease Model 2007;

162. Wang.P, Zaijie.W. Animal and cellular models of chronic pain. Advanced drug

delivery reviews 2003; 55:945-969.

163. Plant Families. Botany Dept, Univ. of Hawaii, Hawaii, (botany.hawaii.edu),

2004.

164. Caesalpinia pulcherrima. Floridata. Tallahassee, Florida, (floridata.com) 2004.

165. Robert A. DeFilipps. Useful Plants of the Commonwealth of Dominica, West

Indies. Smithsonian Institution, Washington, D.C. 1998.

166. KhareCP,Indian Medicinal Plants - An Illustrated Dictionary, spriger publications

2007:118.

References

236

167. Pawar CR, Mutha RE, Landge AD, Jadhav RB and Surana SJ. Antioxidant and

cytotoxic activities of Caesalpinia pulcherrima wood. Ind J Biochem&Biophys

2009;46:198-200.

168. Pherson DMC, Geoffrey A, Cordell, Fong HS. peltocynoids and

homoisoflavonoids from caesalpinza pulcherrima. Phytochemistry 1983; 22(12): 2835-

2838

169. Pherson DMC, Che CT, Geoffrey A, and Fong HS. Diterpenoids from

Caesalpinia pulcherrima. Phytochem 1986; 25(1): 167-170.

170. Awasthi KK, Anoop K and MIstit K. Two Ellagitannins from the stem bark of

Caesalpinia pulcherrima. Phytochem 1980;19: 1995-1997.

171. Ragasa CY, Ganzon J, Hoflena J, Tamboong B, and Rideout JA. A New

FuranoidDiterpene from Caesalpinia pulcherrima. Chem Pharm Bull 2003; 51(10): 1208-

1210.

172. Srinivas KVNS, Rao YK, I. Mahender, Das B,Krishna KVSR, Hara KK, Murty

USN. Flavanoids from Caesalpinia pulcherrima. Phytochem 2003; 63:789–793.

173. Yusuf AA, MofioBM, Ahmed AB. Nutrient Contents of Pride of Barbados

(Caesalpinia pulcherrima Linn.) Seeds. Pakis JNutri 2007; 6 (2): 117-121.

174. Pranithanchai W, Karalai C, Ponglimanont C, Sanan S, Kan

C.Cassanediterpenoids from the stem of Caesalpinia pulcherrima.Phytochem 2009; 70:

300–304.

175. Chiang LC,Chiang W, Liuand Lin CC. In vitro antiviral activities of Caesalpinia

pulcherrima and its related flavonoids. J AntimicroChemother2003; 52: 194–198.

References

237

176. Anil K, Nirmala. Gastric antiulcer Activity of the Leaves of Caesalpinia

pulcherrima. Ind J of Pharm Scien 2004; 66(5):676-678.

177. Chakraborthy GS, Kaushik KN.Antimicrobial Activity of Leaf Extracts of

Caesalpinia pulcherrima (Linn.). J Herb Medic&Toxicol 2009; 3 (1) 65-67.

178. Pawar CR, Mutha RE, Landge AD and Surana SJ. Antioxidant and cytotoxic

activities of Caesalpinia pulcherrima wood. Ind J Biochem&Biophys 2009; 46: 198-200.

179. Soisuwan S, Mapaisansin W, Samee W, and Kamkaen N. Development of

Peacock flower extract as Anti-Wrinkle formulation. J Health Res 2010; 24(1): 29-34.

180. Patel SS, Verma NK, Chatterjee C, Gauthaman K, Screening of Caesalpinia

pulcherrima Linn Flowers for Analgesic and Anti-inflammatory Activities. Internat J

Appl Res Nat Prod 2010; 3(3):1-5.

181. Utpal B, Lubna H, Vaskor B, Rahman AA. Anti-inflammatory and

neuropharmacological activities of Caesalpinia pulcherrima barkRes J

PharmaceuBiol&ChemSci2011; 2(1): 77-84.

182. Satwadhar ND, Mehta P, Patil S, Mute V. Evaluation of Anthelmintic activity of

Caesalpinia pulcherrima Bark against PheretimaPosthuma. Int J Pharm PharmSci 2012:

4(1), 76-77.

183. The Wealth of India, A Dictionary of Indian Raw Materials and Industrial

Products. CSIR New Delhi: 1959. p. 56-7. (Vol 2).

184. Kurien JC. Plants that heal. 4th ed. Pune: Orient Watchman Publishing House;

2001. p. 48, 82. (Vol 1)

185. Reddy MV, Reddy MK. A flavonone and a dihydrodibenzoxepin from Bauhinia

variegata. Phytochemistry 2003;64:879-82.

References

238

186. Sharma RN, Saxena VK. In vitro antimicrobial efficacy of leaves extracts of

Bauhinia variegata Linn. Asian J Chem 1996;8(4):811-2.

187. Rajkapoor B, Jayakar B, Anandan R, Kavimani. Anti-ulcer effect of Bauhinia

variegata Linn. in rats. J Nat Rem 2003;2/3:215-7.

188. Yadava RN, Reddy VM. Anti-inflammatory activity of a novel flavanol glycoside

from Bauhinia variegata Linn. Nat Prod Res 2003;17:165-9.

189. Rajkapoor B, Jayakar B, Murugesh N. Antitumor activity of Bauhinia variegata

Linn. on Dalton's ascytic lymphoma. J Ethnopharmacol 2003;89(1):107-9.

190. Bodakhe SH, Ram A. Hepatoprotective properties of Bauhinia variegata bark

Extract. Yakugaku Zasshi 2007;127(9):1503-7.

191. Oliva MLV, Sampaio MU, Action of plant proteinase inhibitors on enzymes of

physiopathological importance, An Acad Bras Cienc, 81(3), 2009, 615-621.

192. Agarwal RC, Pandey S, Evaluation of anticarcinogenic and antimutagenic

potential of Bauhinia variegata extract in Swiss albino mice, Asian Pacific Journal of

Cancer Prevention, 10(5), 2009, 913-916.

193. Mohamed Mona A. Mammoud Madeha R. Hayen Heiko. Evaluation of

Antinociceptive and Anti-Inflammatory Activities of a New Triterpene Saponin from

Bauhinia variegata Leaves . A Journal of Biosciences 2009;64(6): 798-808

194. Rajani GP, Purnima A. In vitro antioxidant and antihyperlipidemic activity of

Bauhinia variegata Linn. Indian J Pharmacol 2009 oct;41(5)227-32.

195. Patil J. K, Patel M. R, Sayyed H. Y et al in-vitro immunomodulatory activity of

Bauhinia variegate Linn (Caesalpiniaceae) stem bark extracts n human neutrophils..

Pharma Science Monitor 2012;3(1) 1-12.

References

239

196. Frankish N, de Souza Menezes F, Mills C, Sheridan H, Enhancement of Insulin

Release from the ß-Cell Line INS-1 by an Ethanolic Extract of Buahinia variegata and Its

Major Constituent Roseoside, Planta Med, 76, 2010, 995-997.

197. Sharma R K; Rajani G. P. Sharma V et al. Effect of Ethanolic and Aqueous

Extracts of Bauhinia Variegata Linn. on Gentamicin-Induced Nephrotoxicity in Rats Ind

J Pharma Edu Res 2011;45 (2):192-198.

198. Yamini R, Rajani GP. Analgesic and Anti-Ulcer Activities of Ethanol and

Aqueous Extracts of Root of Bauhinia variegata Linn. Indian J Pharmacol 2011;7(5):616-

22.

199. Mandal S, Upadhyay N, Sharma I. A comparative antipyretic activity of the crude

extracts of the ariel parts of Glycosmis pentaphylla and Bauhinia variegate. Recent

Research in Science and Technology 2011;3(7):16-18.

200. Pani Saumya R, Mishra Satyaranjan, Sahoo Sabuj, et al. Nephroprotective effect

of Bauhinia variegata (linn.) whole stem extract against cisplatin-induced nephropathy in

rats. Ind J Pharmacol 2011; 43:200-202.

201. Deore S.L., Deokate U.A., Khadbadi S.S., Komal Moon. Caesalpinia bonducella

F - An Overview. Report and Opinion 2010; 2:83-90.

202. Seema Chauhan, Richa Singh. Phenology and Reproductive Biology

of Caesalpinia bonducella (L.) Flem. (Fabaceae). The International Journal of Plant

Reproductive Biology 2010; 2(2): 1-7.

203. Kirthikar, K.R., Basu, B.D. Indian Medicinal Plants, vol. 2.edition 1987,843-844.

204. Nadkarni K.M., Indian Materia Medica, 3 edition, Popular Prakashan Pvt. Ltd. ,

Bomaby,Vol. 1, edition 1991,415.

References

240

205. Athar Ata, Elikana M. Gale, Radhika Samarasekera, . Bioactive chemical

constituents of Caesalpinia bonduc (Fabaceae). Phytochemistry Letters 2009;2: 106–109.

206. Yadav Prem P., Ranjani Maurya, Jayanta Sarkar, Ashish Arora, Sanjeev

Kanojiya, Sudhir Sinha, Ram Raghuvir, Shrivastav M.N. Cassane Diterpenes from

Caesalpinia bonduc. Phytochemistry 2009;70, 256–261.

207. Shigetoshi Kadota, Suresh Awale, Yasuhiro Tezuka. Cassane- and Norcassane-

Type Diterpenes from Caesalpinia crista of Indonesia and Their Antimalarial Activity

against the Growth of Plasmodium falciparum. J. Nat. Prod., 2005; 68 (5),706–710.

208. Satnami D.K., YadavaR.N. Potential Phytochemical from Caesalpinia CristaLinn

.Research Journal Of Phytochemistry2011;22-31.

209. Kannur D.M., Hukkeri V.I.,Akki K.S. Adaptogenic activity of Caesalpinia

bonduc seed extracts in rats. Journal of Ethnopharmacology 2006;108 ,327-331.

210. Ganesh H Wadkar, Sandeep R Kane, Sunil S. Matapati, Mahesh G. Hogade, . In-

vitro anthelmintic activity of Caesalpinia bonducella (Linn). Flem. leaves. Journal of

Pharmacy Research 2010;3(5),926-927.

211. Jabbar Abdul, Arfan Zaman Muhammad, Iqbal Zafar, Yaseen

Muhammad,Shamim Asim. Anthelmintic activity of Chenopodium album (L.) and

Caesalpinia crista (L.)against trichostrongylid nematodes of sheep. Journal of

Ethnopharmacology 2007;114:86-91.

212. Shantanu Kale , Gunratna Gajbhiye , Nakul Chaudhari. Anti-inflammatory effect

of petroleum ether extract of Caesalpinia bonduc (L.) Roxb seed kernel in rats using

carrageenan-induced paw edema. International Journal of PharmTech Research 2010;

2:750-752.

References

241

213. ShuklaShruti, Mehta Archana, Mehta Pradeep,Vyas Suresh prasad,shukla Savita.

Studies on anti in?ammatory, antipyretic and analgesic properties of Caesalpinia

bonducella F. seed oil in experimental animal models. Food and Chemical Toxicology

2010;48:61-64.

214. Rao K.S.J.,Ramesh B.N.,Indi S.S. Anti-amyloidogenic property of leaf aqueous

extract of Caesalpinia crista. Neuroscience Letters 2010; 475:110-114.

215. M. Asif Saeed,Sabir A.W. Antibacterial activity of Caesalpinia bonducella seeds.

Fitoterapia 2001;72:807-809.

216. Rajesh Dabur, Tasleem Arif, Naresh Kumar, Archana Hole, Mandal T.K et al. In

vitro and in vivo antimicrobial activities of seeds of Caesalpinia bonduc (Lin.) Roxb.

Journal of Ethnopharmacology 2009; 123:177–180.

217. Kannur D.M., Hukkeri V.I.,Akki K.S. Antidiabetic activity of Caesalpinia

bonducella seed extracts in rats. Fitoterapia 2006; 77:546-549.

218. Rastogi s.,kulshreshtra D.K.Chatterjre R.K.,Murthy P.K.,(2008).Antifilarial

activity of caesalpinia bonducella against experimental filarial infection.indian j.

medicine res 2008;128:65-70.

219. Shruti Shukla , Archana Mehta , Jinu John , Siddharth Singh , Pradeep Mehta ,

Suresh Prasad Vyas,(2009). Antioxidant activity and total phenolic content of ethanolic

extract of Caesalpinia bonducella seeds. Food and Chemical Toxicology 47, 1848–1851.

220. R. Sambath Kumar, K. Asok Kumar, N. Venkateswara Murthy. Hepatoprotective

and antioxidant effects of caesalpinia bonducella on carbon tetrachloride-induced liver

injury in rats. nternational Research Journal of Plant Science 2010;(3),062-068.

References

242

221. Kshirsagar Sunil N. Nootropic Activity of dried Seed Kernels of Caesalpinia

crista Linn against Scopolamine induced Amnesia in Mice. International Journal of

PharmA Tech Research 2011;3(1):104-109.

222. Shukla S,Mehta A, John J, Pradeep M et al. Immunomodulatory activities of the

ethanolic extract of Caesalpinia bonducella seeds. Journal of Ethnopharmacology

2009;125,252-256.

223. Singh Virendra Kumar, Sharma Pramod Kumar, Dudhe Rupesh, Kumar Nitin,

(2011). Immunomodulatory effects of some traditional medicinal plants. J. Chem. Pharm.

Res., 2011, 3(1):675-684.

224. Leaf extract of Caesalpinia bonduc Roxb. (Caesalpiniaceae) induces an increase

of contractile force in rat skeletal muscle in

situ. thefreelibrary.com/Leaf+extract+of+Caesalpinia+bonduc+Roxb.+(Caesalpiniaceae)

+induces+an...-a0115835565

225. Emmanuel Nathala, Swaran Dhingra, (2006). Biological Effects of Caesalpinia

crista Seed Extracts on Helicoverpa armigera (Lepidoptera: Noctuidae) and Its Predator,

Coccinella septumounctete (Coleoptera: Coccinellidae). J. Asia-Pacific Entomol. 9(2):

159-164.

226. Kokate CK, Purohit AP, Gokhale SB. Pharmacognosy. 24th ed. Pune: Nirali

Prakashan;2003. p.149-53.

227. Evans WC, Trease. Pharmacognosy. 15th ed. Newyork: oxford Philadelphia;2000.

p. 193, 223, 241.

References

243

228. OECD guidelines for the testing of chemicals (Acute oral toxicity – up and down

procedure). Adopted 23rd march 2006. [cited 2008 Jun 20]; Available

from:URL:www.oecd.org.

229. Vogel GH. Drug Discovery and Evaluation, Pharmacological Assays, Springer-

Verlag, Berlin, Heidelberg, 2nd ed, 2002; pp211,213 397,697.

230. Naik SR, PandaVS. Cardioprotective activity of Polyherbal extracts in

experimental myocardial necrosis in rodents: an evidence of antioxidant activity. J Compl

Integr Med 2008;5:35.

231. Vaibhav Patel, Aman Upaganlawar, Rishit Zalawadia, R. Balaraman.

Cardioprotective effect of melatonin against isoproterenol induced myocardial infarction

in rats: A biochemical, electrocardiographic an histoarchitectural evaluation. European

Journal of Pharmacology 644 (2010) 160–168.

232. Sharma AK, Kishor K, Sharma D et al. cardioprotective activity of ethanolic

extract of Tinospora cardiofolia (wild) Mirs in calcium chloride induced arrhythmia in

rats. Journal of Biochemical Research 2011:25(4):1-8.

233. Sharma AK, Srinivasan BP. Triple glimepisode plus mtformin thrapy on

cardiovascular risk biomarker and diabetic cardiopathy in insulin resistances type 2

diabetic mellitus rats. Eur J Pharm Sci 2009;38:433-44.

234. Al-Obaid AM, EI Subbagh HI, Al Shabanah OA, Mahran MA. Synthesis and

biological valuation of new cyclopentno [b] thiophen derivative as local anaesthetic and

antiarrhythemic agents. Pharmazine 1998;53:24-8.

References

244

235. Guo guangwang, Xiao Hua Lu, Wei Li. Protective Effects of Luteolin ondiabetic

Nephropathy in STZ-Induced Diabetic Rats. Evidence-Based Complementary and

Alternative Medicine Volume 2011:1-7.

236. Akbarzadeh. A ,Norouzian.N, Mehrabi.M,A,Jamshidi et al. Induction of diabetes

by streptozotocin in rats. Indian journal of clinical biochemistry 2007; 22 (2): 60-64.

237. Andersen. H, Gadeberg.P, Brock. B et al, Muscular atrophy in diabetic

neuropathy: astereologicalmagneticresonanceimagingstudy.Diabetologia 1997;40: 1062–

1069.

238. Verma.V, Pooja. Evaluation of Protective Effects of Euphorbia thymifolia Linn

against Streptozotocin induced Diabetic Neuropathy in Rats. RJPBCS 2011;2(3):623

239. Andersen H, Poulsen.PL, Mogensen et al. Isokinetic muscle strength in long-term

IDDM patients in relation to diabetic complications.Diabetes 1996;45:440–445.

240. Bianchi.R, Buyukakilli.B,Brines.M et al Erythropoietin both protects from and

reverses experimental diabetic neuropathy 2004;101(3)

241. Nigel A. Calcutt’, Michael C, Jorgeac, et al. Tactile allodynia and formalin

hyperalgesia in streptozotocin-diabetic rats. Effects of insulin, aldose reductase inhibition

and lidocaine. Pain 1996; 68:293-299.

242. Mohsen Khalili.The Effect of Oral Administration of Withania Somnifera Root on

Formalin-Induced Pain in Diabetic Rats. Basic and clinical neuroscience 2009;1

243. Oral Administration of Vanadate Normalizes Blood Glucose Levels in

Streptozotocin-treated Rats. The journal of biological chemistry 1987; 262(14): 6658-

6662.

References

245

244. Arora. S, Ojha.S, Vohora.D. Characterizations of Streptozotocin Induced Diabetes

Mellitus in Swiss Albino Mice. Global Journal of Pharmacology 2009; 3(2): 81-84.

245. Pioglitazone does not enhance the effectiveness of lifestyle modification in

preventing conversion of impaired glucosetolerance to diabetes in Asian Indians: results

of the Indian Diabetes Prevention Programme-2 (IDPP-2). Diabetologia 2009;

52:10191026

246. Biochemical changes in experimental diabetes before and after treatment with

mangifera indica and psidium guava extracts int j pharm biomed sci. 2011;2(2):29-41.

247. Sivajothia.V, Dey.A .Antihyperglycemic, Antihyperlipidemic and Antioxidant

Effectof Phyllanthus rheedii on Streptozotocin Induced Diabetic Rats.Iranian Journal of

Pharmaceutical Research 2008; 7 (1): 53-59

248. Kumar.P, Annamalai.A.R, Thakur R.S. Anti nociceptive property of Embilica

officinalis in high fat diet/low dose streptozotocin induced diabetic neuropathy in rats.

249. Negi.G, Kumar.A, Ravinder K. et al. Functional and biochemical evidence

indicating beneficial effect of Melatonin and Nicotinamide alone and in combination in

experimental diabetic neuropathy.Neuropharmacology 2010.;58:585-592.

250. Mukherjee.P, Ahamed.N, Kumar.A. Protective effect of biflavones from

Araucaria bidwillii Hook in rat cerebral ischemia/reperfusion induced oxidative stress.

Behaviour brain research 2007; 178:221-228.

251. Simple spectroscopic Methods for estimating Brain Neurotransmitters,

Antioxidant Enzymes of Laboratory animals like Mice: A review.

252. Andrea.M,Vincent.K,James.W et al. Oxidative stress in the pathogenesis of

diabetic neuropathy 2004 ;25(4):612–628.

References

246

253. Anurag. K, Kanwaljit C. Tocotrienol attenuates oxidative–nitrosative stress and

inflammatory cascadein experimental model of diabetic neuropathy.Neuropharmacology

2009; 57:456-462.

254. Eva L. Feldman. Oxidative stress and diabetic neuropathy new understanding of

an old problem. The journal of clinical investigation 2003;111(4):431-433.

255. Sampath.K, Bhaskar.B,Jgdeeshwar.K.Evaluation of antioxidant antinociceptive

activities oxalis corniculata in diabetic neuropathy in rats 2012.IJP8(2):122-127

256. Sivajothia.V, Dey.A .Antihyperglycemic, Antihyperlipidemic and Antioxidant

Effectof Phyllanthus rheedii on Streptozotocin Induced Diabetic Rats.Iranian Journal of

Pharmaceutical Research 2008; 7 (1): 53-59

257. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol 1985;17:291–300.

258. Baroldi, G. Myocardial necrosis: the need for definition. J. Mol. Cell. Cardiol

1972; 6, 401–402.

259. Yeager, J.C., Iams, S.G. The haemodynamics of isoproterenol induced cardiac

failure in rats. Circ. Shock 1981; 81:151–163.

260. Rajadurai, M., Prince, P.S.M. Preventive effect of naringin on lipid peroxides and

antioxidants in isoproterenol-induced cardiotoxicity in Wistar rats: biochemical and

histopathological evidences. Toxicology 2006;228, 259–268.

261. Upaganlawar, A., Gandhi, C., Balaraman, R. Effect of green tea and vitamin E

combination in isoproterenol induced myocardial infarction in rats. Plant Foods Hum.

Nutr 2009; 64, 75–80.

References

247

262. Peacock WE, Hollander JE, Smalling RW, Bresler MJ. Reperfusion strategies in

the emergency treatment of ST-segment elevation myocardial infarction. Am J Emerg

Med 2007; 25: 353-366.

263. Punithavathi VR, Stanely Mainzen Prince P. The cardioprotective effects of a

combination of quercetin and α-tocopherol on isoproterenol-induced myocardial infarcted

rats. J Biochem Mol Toxicol 2011; 25: 28-40.

264. Ithayarasi AP, Padmavathy VN, Devi SC. Effect of alpha-tocopherol on

isoproterenol induced myocardial infarction in rats–electrocardiographic biochemical and

histological evidences. Ind J Physiol Pharmacol 1996;40:297–302.

265. Singal, P.K., Kapur, N., Dhillon, K.S., Beamish, R.E., Dhalla, N.S., 1982. Role of

free radicals in catecholamine induced cardiomyopathy. Can. J. Physiol. Pharmacol. 60,

1390–1397.

266. Priscilla, D.H., Prince, P.S.M. Cardioprotective effect of gallic acid on cardiac

troponin-T, cardiac marker enzymes, lipid peroxidation products and antioxidants in

experimentally induced myocardial infarction in Wistar rats. Chem. Biol. Interact 2009.

179, 118–124.

267. Jayalakshmi, R., Thirupurasundari, C.J., Devaraj, S.N. Pretreatment with

alcoholic extract of Crataegus oxycantha (AEC) activates mitochondrial protection

during isoproterenol — induced myocardial infarction in rats. Mol. Cell. Biochem 2006;

292, 59–67.

268. Lil, J.L., Stantman, F.N., Lardy, H.A. Antioxidant enzyme systems in rat liver

andskeletal muscle. Arch. Biochem. Biophys 1988; 263, 150–156.

References

248

269. Karthikeyan K, Bai BR, Gauthaman K, Satish KS, Devaraj SN. Cardioprotective

effect of the alcoholic extract of Terminalia arjuna bark in an in vivo modelof myocardial

ischemia reperfusion injury. Life Sci 2003;73:2727–30.

270. Senthil Kumar H, Anandan R, Santhosh Kumar M. Cardioprotective effect of

Picorrhiza kurrooa against isoproterenol induced myocardial stress in rats. Fitotherapia.

2001; 72: 402.

271. Medine-Benchekor S, Brousseau T, Richard F, Benhamamouch S, Amouyel P.

Blood lipid concentrations and risk of myocardial infarction. Lancet. 2001; 358: 1064-

1065.

272. Gürgün C, Ildızlı M, Yavuzgil O, Sin A, Apaydın A, Cınar C, Kültürsay H. The

effects of short term statin treatment on left ventricular function and inflammatory

markers in patients with chronic heart failure. Int. J. Cardiol. 2008; 123: 102–107.

273. Gokkusu C, Mostafazadeh T. Changes of oxidative stress in various tissues

bylong-term administration of vitamin E in hypercholesterolemic rats. Clin. Chim. Acta.

2003; 328: 155–161.

274. Brewer, H.B. Hypertriglyceridemia: changes in the plasma lipoproteins associated

with an increased risk of cardiovascular disease. Am. J. Cardiol1999;13, 3F–12F

275. Constanze Schmidt, Jana Kisselbach, Patrick A Schweizer et al. The pathology

and treatment of cardiac arrhythmias: focus on atrial fibrillation Vascular Health and Risk

Management 2011:7 193–202.

276. Frolkis V.V., Frolkis R. A. · Dubur G.Ya. Antioxidants as Antiarrhythmic Drugs.

Cardiology 1987;74:124–132

References

249

277. Rees DA, Alcolado JC. Animal models of diabetes mellitus. Diabet Med

2005;22:359-70.

278. Morrow TJ. Animal models of painful diabetic neuropathy: the STZ rat model.

Curr Protoc Neurosci; 2004 [Chapter 9]: Unit 9.18.

279. Ya-Hong Gong 1, Xue-Rong Yu 1, Hui-Li Liu 2, Nan Yang et al. Antinociceptive

effects of combination of Tramadol and Acetaminophen on painful diabetic neuropathy

in streptozotocin-induced diabetic rats. Acta Anaesthesiologica Taiwanica 2011;49: 16-

20.

280. James Mu,Woods.J, Sinha .R Chronic Inhibition of Dipeptidyl Peptidase-4 With a

Sitagliptin Analog Preserves Pancreatic _-Cell Mass and Function in a Rodent Model of

Type 2,1.Diabetes 2010;2(3):23-24.

281. Simple spectroscopic Methods for estimating Brain Neurotransmitters,

Antioxidant Enzymes of Laboratory animals like Mice: A review.

282. Akbarzadeh. A ,Norouzian.N, Mehrabi.M,A,Jamshidi et al. Induction of diabetes

by streptozotocin in rats. Indian journal of clinical biochemistry 2007; 22 (2): 60-64.

283. Pioglitazone does not enhance the effectiveness of lifestyle modification in

preventing conversion of impaired glucosetolerance to diabetes in Asian Indians: results

of the Indian Diabetes Prevention Programme-2 (IDPP-2). Diabetologia 2009;

52:10191026

284. Biochemical changes in experimental diabetes before and after treatment with

mangifera indica and psidium guava extracts int j pharm biomed sci. 2011;2(2):29-41.

References

250

285. Rimbau.V,Risco.E, Canigueral.S.Antiinflammatory Activity of Some Extracts

from Plants used in the Traditional Medicine of North-African Countries. Spanish

Comision Interministerial de Ciencia y Tecnologia1995.

286. Smith, A.G. and J.R. Singleton, Impaired glucose tolerance and neuropathy.

Neurologist, 2008. 14(1): p. 23-9.

287. Jamali, R. and S. Mohseni, Differential neuropathies in hyperglycemic and

hypoglycemic diabetic rats. J Neuropathol Exp Neurol, 2006. 65(12):1118-25.

288. Sami Algaidi. The effect of antioxidants on experimentally induced diabetic

peripheral neuropathy in adult male albino rats. Journal of American Science, 2011,

(12);1-7.